Bridge City Capital LLC Acquires 673 Shares of Amedisys, Inc. (NASDAQ:AMED)

Bridge City Capital LLC increased its stake in shares of Amedisys, Inc. (NASDAQ:AMED – Get Rating) by 3.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,815 shares of the health services provider’s stock after buying an additional 673 shares during the quarter. Bridge City Capital LLC’s holdings in Amedisys were worth $1,918,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. First Horizon Advisors Inc. grew its position in Amedisys by 862.5% during the second quarter. First Horizon Advisors Inc. now owns 385 shares of the health services provider’s stock worth $40,000 after buying an additional 345 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Amedisys during the second quarter worth approximately $44,000. Covestor Ltd grew its position in Amedisys by 88.9% during the first quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock worth $56,000 after buying an additional 152 shares in the last quarter. Lazard Asset Management LLC bought a new position in shares of Amedisys in the 1st quarter valued at $68,000. Finally, Hallmark Capital Management Inc. lifted its stake in shares of Amedisys by 7.6% in the 2nd quarter. Hallmark Capital Management Inc. now owns 1,253 shares of the health services provider’s stock valued at $132,000 after acquiring an additional 88 shares during the last quarter. Institutional investors and hedge funds own 96.17% of the company’s stock.

Amedisys Stock Performance

Shares of Amedisys stock traded down $1.74 during mid-day trading on Wednesday, hitting $94.92. 132,250 shares of the stock were exchanged, compared to its average volume of 437,731. Amedisys, Inc. has a 12 month low of $79.30 and a 12 month high of $179.91. The company has a 50-day simple moving average of $86.98 and a 200 day simple moving average of $101.07. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market capitalization of $3.08 billion, a P/E ratio of 26.05, a P/E/G ratio of 2.26 and a beta of 0.96.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on AMED shares. Truist Financial lowered their target price on Amedisys from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Friday, October 28th. StockNews.com lowered Amedisys from a “buy” rating to a “hold” rating in a research report on Thursday, January 26th. Stephens lowered their target price on Amedisys from $122.00 to $106.00 and set an “equal weight” rating for the company in a research report on Friday, November 11th. Benchmark lowered their target price on Amedisys from $135.00 to $120.00 and set a “buy” rating for the company in a research report on Wednesday, January 25th. Finally, Oppenheimer lowered their target price on Amedisys from $145.00 to $125.00 and set an “outperform” rating for the company in a research report on Thursday, January 19th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Amedisys presently has a consensus rating of “Hold” and a consensus target price of $128.25.

Amedisys Company Profile

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.